US · Healthcare · Drug Manufacturers - General
EPS came in at -0.13 against a street estimate of -0.26 — a beat of 50.0%.
Analysts rate Merck & Company Inc a buy (19 buy, 8 hold, 0 sell out of 27) with an average price target of $158.44.
MIXED Merck delivered 5% revenue growth and raised 2026 revenue guidance, but Terns acquisition charges drove a reported EPS loss and management flagged moderating KEYTRUDA growth. Q2 FY26 International GARDASIL sales grew 6%; U.S. GARDASIL was roughly flat, while U.S. WINREVAIR prescription trends improved. Analysts focused on sac-TMT positioning, TL1A efficacy, new-product adoption and longer-term growth. Management emphasized positive data, rapid trial advancement and remaining readouts before firm conclusions. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.20% |
| Vanguard Capital Management, LLC | 6.54% |
| State Street Corp | 4.88% |
| Wellington Management Company LLP | 3.50% |
| Vanguard Portfolio Management, LLC | 2.75% |
| Geode Capital Management, LLC | 2.46% |
| Charles Schwab Investment Management Inc | 2.20% |
| Morgan Stanley - Brokerage Accounts | 1.97% |
| Document | Date |
|---|---|
| Board / officer change · Q4 2026 OTHER NOTABLE POINTS • Merck & Co. announced the election of Paul J. Diaz to its Board of Directors, effective November 1, 2026. • Mr. Diaz was appo | 2026-10-13 |
| Quarterly report · Q2 2026 MERCK & CO., INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Sales (Q2 2026): $16,607 million vs. $15,806 million (Q2 2025) — up 5.1% • Sales (6M 202 | 2026-08-07 |
| Results announced · Q3 2026 MERCK & CO., INC. - FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • 2Q 2026 Sales: $16,607 million (up 5% vs 2Q 2025: $15,806 million) • J | 2026-08-04 |
| Shareholder vote results · Q2 2026 MERCK & CO., INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Shareholder Meeting held May 26, 2026 • Total votes cast: approximately 1.857 billion | 2026-05-28 |
| Company announcement · Q2 2026 MERCK & CO., INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Merck closed an underwritten public offering of $6,000,000,000 in new debt securities on May | 2026-05-22 |
| Quarterly report · Q1 2026 MERCK & CO., INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Q1 2026 Sales: $16,286 million (vs. $15,529 million in Q1 2025) • Q1 2026 Net Loss: $(4, | 2026-05-04 |
| Results announced · Q2 2026 MERCK Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total Worldwide Sales: $16.3 billion (5% growth; 3% excluding foreign exchange) • GAAP Lo | 2026-04-30 |
| Proxy statement · Q2 2026 MERCK & CO., INC. — PROXY SUMMARY FOR RETAIL INVESTORS CEO TOTAL COMPENSATION Robert M. Davis (Chairman, CEO, President): • 2025 Base Salary: $1,650 | 2026-04-08 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.85 / share ex-date Sep 15, 2026 · pay Oct 7, 2026 | 2026-09-15 |
| Dividend | $0.85 / share ex-date Jun 15, 2026 · pay Jul 8, 2026 | 2026-06-15 |
| Dividend | $0.85 / share ex-date Mar 16, 2026 · pay Apr 7, 2026 | 2026-03-16 |
| Dividend | $0.85 / share ex-date Dec 15, 2025 · pay Jan 8, 2026 | 2025-12-15 |
| Dividend | $0.81 / share ex-date Sep 15, 2025 · pay Oct 7, 2025 | 2025-09-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Merck & Company Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.